Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants

NCT06340958 is registered in ClinicalTrials.gov with Clexio Biosciences Ltd. as lead sponsor.

NCT NCT06340958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants
Lead sponsor
Clexio Biosciences Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 18, 2024
Completion date
November 25, 2025
Enrollment
99 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

adjunctive treatment of major depressive disorder (mdd)